The price of Prime Medicine Inc (NASDAQ:PRME) shares last traded on Wall Street rose 10.73% to $4.54.
PRME stock price is now 150.36% away from the 50-day moving average and 73.38% away from the 200-day moving average. The market capitalization of the company currently stands at $596.08M.
With the price target maintained at $1.50, Citigroup recently Downgraded its rating from Buy to Neutral for Prime Medicine Inc (NASDAQ: PRME). , while ‘H.C. Wainwright’ rates the stock as ‘Neutral’
In other news, Liu David R., 10% Owner bought 21,000 shares of the company’s stock on Jun 30 ’25. The stock was bought for $52,830 at an average price of $2.52. Upon completion of the transaction, the 10% Owner now directly owns 20,240,945 shares in the company, valued at $91.89 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 23 ’25, 10% Owner Liu David R. bought 21,000 shares of the business’s stock. A total of $45,402 was incurred on buying the stock at an average price of $2.16. This leaves the insider owning 20,219,945 shares of the company worth $91.8 million. A total of 60.67% of the company’s stock is owned by insiders.
During the past 12 months, Prime Medicine Inc has had a low of $1.11 and a high of $6.75. As of last week, the company has a debt-to-equity ratio of 1.13, a current ratio of 4.78, and a quick ratio of 4.78. The fifty day moving average price for PRME is $1.8134 and a two-hundred day moving average price translates $2.61855 for the stock.
The latest earnings results from Prime Medicine Inc (NASDAQ: PRME) was released for 2025-03-31. The net profit margin was -5252.50% and return on equity was -115.21% for PRME. The company reported revenue of $1.45 million for the quarter, compared to $0.59 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 146.02 percent.
